Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 8-K (Current Report)
Date of Report: March 3, 2022
Reporting Period: The filing announces financial results for the year ended December 31, 2021, and provides a business update.
Key Financial Metrics
The provided text is a cover sheet and index for the Form 8-K. It references a press release (Exhibit 99.1) containing the actual financial data but does not list specific figures within this document.
- Revenue, Profit, Cash Flow, Margins: Not provided in this text; data is contained in the referenced Exhibit 99.1.
- Debt and Liquidity: Not provided in this text; data is contained in the referenced Exhibit 99.1.
Material Changes
The filing text does not provide specific comparative data or material changes versus the prior period. It serves only to notify investors that the results for the year ended December 31, 2021, have been issued.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on March 3, 2022, regarding its financial results and business update.
Legal Disclaimer: The information in this Current Report and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It shall not be incorporated by reference into any registration statement unless expressly set forth by specific reference.
Emerging Growth Company: The registrant is an emerging growth company.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for the year ended December 31, 2021.
- Verify the "business update" details regarding clinical trial progress or pipeline milestones mentioned in the press release.
- Confirm the company's cash runway and burn rate based on the full financial statements referenced in the press release.